Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.53 |
| ▸ | BACE1 | P56817 | 4/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026659 | 1.00 | GSK3B (0.53) | GSK3BBACE1LCKNPC1RAB9A | |
| SCHEMBL6191841 | 0.82 | LCK (0.55) | GSK3BBACE1LCKNPC1RAB9A | |
| SCHEMBL10953297 | 0.78 | GSK3B (0.63) | GSK3BBACE1LCKNPC1RAB9A | |
| SCHEMBL10953300 | 0.78 | GSK3B (0.63) | GSK3BBACE1LCKNPC1RAB9A | |
| SCHEMBL20024692 | 0.77 | LCK (0.77) | GSK3BBACE1LCKNPC1RAB9A | |
| SCHEMBL14786203 | 0.77 | LCK (0.77) | GSK3BBACE1LCKNPC1RAB9A | |
| SCHEMBL14691485 | 0.76 | LCK (0.62) | GSK3BBACE1LCKNPC1RAB9A | |
| SCHEMBL8913590 | 0.76 | LCK (0.81) | GSK3BBACE1LCKNPC1RAB9A | |
| SCHEMBL8913578 | 0.76 | LCK (0.81) | GSK3BBACE1LCKNPC1RAB9A | |
| SCHEMBL6582106 | 0.76 | GSK3B (0.60) | GSK3BBACE1LCKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134884-A1 | Neovascularization inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1277730-A1 | NEOVASCULARIZATION INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134884-A1 | Neovascularization inhibitors | VEGFA, FLT1, FLT4 | GSK3B 415/4885BACE1 2367/4885LCK 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.